Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia.
Article Details
- CitationCopy to clipboard
Benes LB, Bassi NS, Davidson MH
Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia.
Vasc Health Risk Manag. 2016 Dec 12;12:481-490. doi: 10.2147/VHRM.S58149. eCollection 2016.
- PubMed ID
- 28003756 [ View in PubMed]
- Abstract
The 2013 American College of Cardiology/American Heart Association guidelines on cholesterol management placed greater emphasis on statin therapy given the well-established benefits in primary and secondary prevention of cardiovascular disease. Residual risk may remain after statin initiation, in part because of triglyceride-rich lipoprotein cholesterol. Several large trials have failed to show benefit with non-statin cholesterol-lowering medications in the reduction of cardiovascular events. Yet, subgroup analyses showed a benefit in those with hypertriglyceridemia and lower high-density lipoprotein cholesterol level, a high-risk pattern of dyslipidemia. This review discusses the benefits of omega-3 carboxylic acids, a recently approved formulation of omega-3 fatty acid with enhanced bioavailability, in the treatment of dyslipidemia both as monotherapy and combination therapy with a statin.
DrugBank Data that Cites this Article
- Drugs
- Pharmaco-metabolomics
Drug Drug Groups Metabolite Change Description Omega-3-acid ethyl esters Approved Investigational Small dense LDL cholesterol decreased Omega-3-acid ethyl esters decreases the level of Small dense LDL cholesterol in the blood